Search

Displaying results 6801 - 6810 of 7067 in total
  1. Drug

    Ezurpimtrostat

    go.drugbank.com/drugs/DB16458
    Investigational

  2. Drug

    TD-0903

    go.drugbank.com/drugs/DB16463
    Investigational

    TD-0903 was investigated in clinical trials for its potential to treat acute lung injury (ALI) associated with COVID-19, including NCT04350736, NCT05091723 (a pharmacokinetics study in healthy participants

  3. Drug

    CIGB 300

    go.drugbank.com/drugs/DB16464
    Investigational

    CIGB-300, is under investigation in clinical trials for its potential to treat various conditions, including NCT01639638 (recurrent and nonrecurrent condyloma) and NCT01639625 (squamous cell carcinoma and adenocarcinoma of the cervix)

  4. Drug

    Meplazumab

    go.drugbank.com/drugs/DB16465
    Investigational

    Meplazumab is a humanized anti-CD147 antibody being investigated as an add-on therapy in patients with COVID-19 pneumonia.

  5. Drug

    LSALT Peptide

    go.drugbank.com/drugs/DB16472
    Investigational

  6. Drug

    SAB-185

    go.drugbank.com/drugs/DB16491
    Investigational

  7. Drug

    Amubarvimab

    go.drugbank.com/drugs/DB16493
    Investigational

    Amubarvimab (BRII-196) was under investigation in clinical trials (NCT04691180 and NCT04787211) to treat COVID-19, focusing on its safety, tolerability, and efficacy.

  8. Drug

    Romlusevimab

    go.drugbank.com/drugs/DB16494
    Investigational

    Romlusevimab (BRII-198) was under investigation in clinical trials (NCT04479644 and NCT04691180) to treat COVID-19, focusing on its safety, tolerability, and pharmacokinetics.

  9. Drug

    Oleic monoethanolamide

    go.drugbank.com/drugs/DB16495
    Investigational

  10. Drug

    INM005

    go.drugbank.com/drugs/DB16499
    Investigational

    It was studied for pharmacokinetics, efficacy, and safety in a completed trial (NCT04494984). … Additionally, a retrospective cohort study investigated the effectiveness and safety of specific hyperimmune equine serum for severe hospitalized COVID-19 patients (NCT04954235)